Peptides Hormone SupportMuscle BuildingWeight Loss
Tesamorelin
Egrifta
N-terminally stabilized GHRH analog approved to reduce excess visceral fat in HIV lipodystrophy.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 0.0 days
- Bioavailability
- 50%
- Typical dose
- 1–2 mg